Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is N/A as of 2026-10-06T12:01:41.319Z.
Calculation as of: 2026-10-06T12:01:41.319Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
N/A
Market Cap
$83.96M
EV/Assets Ratio
1.30x
TTM Avg
1.91x
3Y Avg
1.49x
5Y Avg
2.37x
Market Cap
$84.70M
EV/Assets Ratio
4.35x
TTM Avg
6.21x
3Y Avg
2.75x
5Y Avg
2.22x
Market Cap
$84.75M
EV/Assets Ratio
0.46x
TTM Avg
0.31x
3Y Avg
0.55x
5Y Avg
0.67x
Market Cap
$81.22M
EV/Assets Ratio
0.67x
TTM Avg
0.82x
3Y Avg
1.86x
5Y Avg
1.86x
Market Cap
$87.86M
EV/Assets Ratio
2.12x
TTM Avg
1.85x
3Y Avg
1.64x
5Y Avg
1.26x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 1.30x | 1.91x | 1.49x | 2.37x |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 4.35x | 6.21x | 2.75x | 2.22x |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.46x | 0.31x | 0.55x | 0.67x |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 0.67x | 0.82x | 1.86x | 1.86x |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 1.36x | 1.36x | 0.84x | 0.70x |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 2.12x | 1.85x | 1.64x | 1.26x |
| electroCore, Inc. (ECOR)vs › | $91.33M | 5.41x | 3.61x | 3.05x | 2.14x |
| Equillium, Inc. (EQ)vs › | $91.68M | 0.60x | 2.47x | 1.52x | 1.10x |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | 1.63x | 0.87x | 0.95x | 1.35x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
